Yolande Lievens
Ghent University Hospital – Ghent University
Co-Chair ESTRO-HERO project
ESTRO president
From science to practice

Methodological developments

Methodological translations

Scientific dissemination & education

Tools & advocacy

Practical applications
NEEDS
optimal radiotherapy utilisation
in European countries

AVAILABLE
equipment & staffing
guidelines
reimbursement
in Europe

ACTIVITY-BASED
COSTING
cost and productivity
at the national level
within European countries

ECONOMIC
EVALUATION
of radiotherapy
treatments and techniques
in Europe

HERO-project

Lievens & Grau. R&O 2012
3 / 10 patients in Europe *do not receive* the radiotherapy they need.
≈ 16% more radiotherapy courses needed in Europe!

Borras et al. R&O 2015

Case Study on Radiotherapy

Report due end of June 2017
The HERO Costing Model

a twofold objective

**Resources**
required & utilized

**Cost of treatments**
technique, fractionation schedule, complexity

RESOURCES

ACTIVITY

RT TREATMENT

Time-Driven ABC

Calculate the cost
Per type of tumour, accounting for complexity and fractionation
HERO reimbursement survey: two aims

1. Give an *overview of the actual status* of radiotherapy reimbursement systems in Europe
   - benchmark with costs
   - align with structure of costing model

2. *Methodological analysis* of the reimbursement systems and *provide guidance* towards novel reimbursement developments
radiotherapy care pathway

20 countries with a FFS system per (some) activity are displayed
release during ESTRO governance week
December 5th 2017, Brussels
Value for National Societies

*Respond to the needs of our national societies*
- Address budget shortages: equipment, personnel, research
- Focus on reimbursement issues
- Comparison with other oncologic disciplines

*Strategic importance*
- Understand the situation of RT in Europe
- Empower ESTRO with information to tackle the most important professional issues at EU level
- NS to advocate for RT in their own country
From HERO to Public Affairs Activities

Contact programme with EU decision makers
Building a community of ambassadors supportive of radiation oncology and forge strategic partnerships

Public Affairs Flyer
Simple messages
Facts and solutions

Advocacy toolkit for NS
Definition of clear messages, for the radiation oncology community to use in engaging with external stakeholders
Aim to raise awareness of radiation oncology amongst relevant audiences (European decision-makers, stakeholders and patients...)

HERO publications
Basis for signature stories and key advocacy messages
From HERO to Public Affairs Activities

PA flyer and toolkit
From HERO to Public Affairs Activities

Contact programme between
ESTRO leadership &
key EU health stakeholders
EU policymakers

- **communicate** key messages from the advocacy toolkit
- **advocate** for the recognition of radiation oncology, awareness
- forge strategic **partnerships** with MEPs, Commission officials and EU stakeholders
Thanks to

Cai Grau
Peter Dunscombe
Josep Borras
Mary Coffey
Lionel Perrier
Judith van Loon
Ben Slotman
Julian Malicki
Marta Bogusz-Czerniewicz
Donal Hollywood
Chiara Gasparotto
Noémie Defourny
Julietta Corral

ESTRO board and office
Thanks to

HERO National Societies collaborators

Arianit Kokobobo, Tirana, Albania; Felix Sedlmayer, Salzburg, Austria; Elena Slobina, Minsk, Belarus; Karen Feyen, Belgium; Olivier De Hertogh, Verviers, Belgium; Philippe Coucke, Liege, Belgium; Roumen Gabrovski, Shoumen, Bulgaria; Tatiana Hadjieva, Sofia, Bulgaria; Jiri Petera, Hradec Kralove, Czech Republic; Karel Odrazka, Pardubice, Czech Republic; Milan Vosmik, Hradec Kralove, Czech Republic; Jesper Grau Eriksen, Odense, Denmark; Jana Jaal, Tartu, Estonia; Ritva Bly, Helsinki, Finland; Bruno Chauvet, Avignon, France; Catherine Dejean, Nice, France; David Azria, Montpellier, France; Michael Baumann, Dresden, Germany; Normann Willich, Munster, Germany; Csaba Polgar, Budapest, Hungary; Zoltan Takacsi-Nagy, Budapest, Hungary; Jakob Johannsson, Reykjavik, Iceland; Moya Cunningham, Dublin, Ireland; Stefano Magrini, Brescia, Italy; Vydmantas Atkocius, Vilnius, Lithuania; Carlo Back, Luxembourg; Michel Untereiner, Esch sur Alzette, Luxembourg; Martin Pirotta, Floriana, Malta; Vanja Karadjinovic, Podgorica, Montenegro; Sverre Levern, Osteras, Norway; Krystof Skladowski, Gliwice, Poland; Boguslaw Maciejewski, Gliwice, Poland; Marian Reinfuss, Krakow, Poland; Maria Lurdes Trigo, Porto, Portugal; Valentin Cernea, Cluj Napoca, Romania; Pavol Dubinsky, Kosice, Slovakia; Segedin Barbara, Ljubljana, Slovenia; Amalia Palacios Eito, Cordoba, Spain; Aurora Rodriguez, Madrid, Spain; Jose Lopez Torrecilla, Valencia, Spain; Ramon Cleries Soler, L’Hospitalet de Llobregat, Spain; Magnus Lagerlund, Kalmar, Sweden; Bert Pastoors, Geneva, Switzerland; Charlotte Beardmore, London, UK; Gaile Smyth, Northern Ireland, UK; Jaap Vaarkamp, Bodelwyddan, Wales, UK; Peter Hoskin, Northwood, UK; Scott Taylor, Edinburgh, Scotland, UK; Roger Taylor, Swansea, Wales, UK; Sara Erridge, Edinburgh, UK